Abstracts tagged "prednisone"

Abstract Number: 2162 • 2016 ACR/ARHP Annual Meeting
Frequent Discussion of Insomnia and Weight Gain with Glucocorticoid Therapy: An Analysis of Twitter Posts
Rikesh Patel¹, Nabarun Dasgupta², Maksim Belousov³, Meghna Jani⁴, Carly Winokur², Goran Nenadic³ and William G Dixon^1,5, ¹Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ²Epidemico Inc., Boston, MA, ³School of Computer Sciences, The University of Manchester, Manchester, United Kingdom, ⁴Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁵Manchester Academic Health Sciences Centre, Health e-Research Centre, Farr Institute for Health Informatics Research, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Glucocorticoid (GC) therapy is used widely in patients with inflammatory diseases. However their effectiveness is offset by a range of potential harms. Clinicians and…
Abstract Number: 24 • 2016 ACR/ARHP Annual Meeting
Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk
Katherine Liao¹, Carol J. Etzel^2,3, Jeffrey D. Greenberg⁴, Hongshu Guan⁵, Joel Kremer⁶ and Daniel H. Solomon⁷, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴New York University School of Medicine, New York, NY, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶The Center for Rheumatology, Albany Medical College, Albany, NY, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) is a major source of morbidity and mortality in RA, but current management goals follow general population recommendations without tailoring based…
Abstract Number: 118 • 2015 ACR/ARHP Annual Meeting
Identifying the Investment Needed to Generate a Durable Prednisone Dose Decrement
Martha Delgado¹, Lorena Wilson², James D. Katz³ and Ann Biehl⁴, ¹the National Institute of Arthritis Musculoskeletal and Skin Diseases, the National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institutes of Health, Bethesda, MD, ³Department of Medicine, Division of Rheumatology, The George Washington University, Washington, DC, ⁴Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD
Background/Purpose: Assessment of the total cost of care requires clinical, epidemiological, patient-centered, and economic data. However, barriers to a value-driven outcome assessment include the resource-intensive…
Abstract Number: 1564 • 2015 ACR/ARHP Annual Meeting
Initiation of Disease Modifying Therapies and Subsequent Weight Change in Rheumatoid Arthritis
Joshua Baker¹, Brian Sauer², Kaleb Michaud³, Grant W. Cannon⁴, Said Ibrahim⁵, Liron Caplan⁶, Lisa A. Davis⁶, Amy C. Cannella⁷ and Ted R. Mikuls⁸, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁴Internal Medicine, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ⁷Section of Rheumatology, University of Nebraska Med Ctr, Omaha, NE, ⁸University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Low body mass index (BMI) predicts adverse outcomes in rheumatoid arthritis (RA), in part due to weight loss among patients with severe disease and…
Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting
Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Ashima Makol¹, Steven R. Ytterberg⁴, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…
Abstract Number: 2656 • 2015 ACR/ARHP Annual Meeting
Analysis of Morning Stiffness Response in Rheumatoid Arthritis Patients with Low Disease Activity Receiving Delayed-Release Prednisone Plus Dmards As Compared to Placebo Plus Dmards
Rieke Alten¹, Robert J. Holt², Jeffrey D. Kent³ and Frank Buttgereit⁴, ¹Charité Univ Medicine, Berlin, Germany, ²College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, ³Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ⁴Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Patient reported outcomes such as morning stiffness are reported frequently in rheumatoid arthritis (RA) patients. But little has been reported about the presence and…
Abstract Number: 3145 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Modified-Release Prednisone in Patients with Polymyalgia Rheumatica: Results of a Multicenter, Randomized, Active-Controlled Phase 3 Study
Maurizio Cutolo¹, Michael Hopp², Stefan Liebscher², Bhaskar Dasgupta³ and Frank Buttgereit⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²Medical Science, Mundipharma Research GmbH & Co. KG, Limburg, Germany, ³Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Polymyalgia rheumatica (PMR) is characterized by persisting proximal pain and morning stiffness of the neck, shoulder and hip girdles of 2 weeks' duration, an…
Abstract Number: 2913 • 2014 ACR/ARHP Annual Meeting
Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Nazim Reshiti², Toni Kaegi³, Axel Finckh⁴, Hendrik Schulze-Koops⁵, Michael H. Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, St. Gallen, Switzerland, ³Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ⁶School of Medicine, University of Colorado, Denver, CO, ⁷Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose Anti-inflammatory and disease-modifying properties of glucocorticoids (GCs) have been demonstrated in patients with rheumatoid arthritis (RA). Better outcomes in trials by combinations of synthetic…
Abstract Number: 2768 • 2014 ACR/ARHP Annual Meeting
Patient Reported Outcomes and Acute Phase Reactants in Polymyalgia Rheumatica in Patients Treated with Prednisone Versus Modified-Release Prednisone
Mauro Betelli, Giulia Erba, Massimo Ricci, Carlo Valena, Elisabetta Allevi, Marta Riva, Giorgia Grosso, Simona Barbarossa, Federica Bonomi and Maria Rosa Pozzi, Department of Internal Medicine, Rheumatology Outpatient Clinic - San Gerardo Hospital – Milano-Bicocca University, Monza, Italy
Background/Purpose Polymyalgia rheumatica (PMR) is a chronic inflammatory disorder of the elderly, characterised by morning stiffness, pain and aching in the hip and shoulder girdles…
Abstract Number: 1665 • 2014 ACR/ARHP Annual Meeting
Efficacy Versus Safety of Prednisone in Lupus Nephritis Since 1988
Tanmayee Bichile¹, Laurence S Magder² and Michelle Petri³, ¹Rehumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose Morbidity and damage due to prednisone use in the treatment of SLE is recognized, but prednisone has been a requisite of lupus nephritis induction…
Abstract Number: 1264 • 2014 ACR/ARHP Annual Meeting
Analysis of Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Severity of Physical Dysfunction after Treatment for Polymyositis and Dermatomyositis
Hidenaga Kawasumi¹, Takahisa Gono¹, Yasushi Kawaguchi¹, Yasuhiro Katsumata¹, Hisae Ichida¹, Akiko Tochimoto¹, Masanori Hanaoka¹, Yuko Okamoto¹, Sayuri Kataoka¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Half of all polymyositis (PM)/dermatomyositis (DM) patients suffer from muscle weakness after initial treatment. Therefore, many patients with PM/DM have trouble with daily living…
Abstract Number: 798 • 2014 ACR/ARHP Annual Meeting
Frequency and Predictive Variables of Relapses in Patients with Biopsy-Proven Giant Cell Arteritis
Luigi Boiardi¹, Giovanna Restuccia², Francesco Muratore¹, Alberto Cavazza³, Luca Cimino⁴, Raffaella Aldigeri⁵, Pierluigi Macchioni¹, Maria Grazia Catanoso⁶, Nicolò Pipitone¹ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁴Ophthalmology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁵Clinical and experimental Medicine, Università di parma, Parma, Italy, ⁶Rheumatology Service, Arcispedale S Maria Nuova, Reggio Emilia, Italy
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis that involves large and medium sized arteries in patients older than 50 years. Relapses and recurrences of…
Abstract Number: 223 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Clinical Vertebral Fractures in Japanese Men and Women with Rheumatoid Arthritis: Results from a Large Prospective Observational Cohort Study
Osamu Ishida¹, Takefumi Furuya², Eisuke Inoue³, Kensuke Ochi², Katsunori Ikari², Atsuo Taniguchi⁴, Hisashi Yamanaka² and Shigeki Momohara⁴, ¹Orthopedics, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) are at high risk of developing vertebral fractures. Previously, utilizing data from our Institute of Rheumatology Rheumatoid Arthritis (IORRA)…
Abstract Number: 1224 • 2013 ACR/ARHP Annual Meeting
Prednisone Has No Effect On Odanacatib Pharmacokinetics In Healthy Subjects
Gene Marcantonio¹, Chengcheng Liu², Stefan Zajic³, Chantal Mahon², David Hreniuk², Anish Mehta⁴, Kate Mostoller², Denise Morris⁵, Hongwei Xue⁵ and S. Aubrey Stoch², ¹Merck & Co., Whitehouse Station, NJ, ²Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ³Merck Sharp & Dohme Corp, Whitehouse Station, NJ, ⁴Merck Sharp & Dohme Corp.,, Whitehouse Station, NJ, ⁵Covance, Madison, WI
Background/Purpose: We evaluated the effect of prednisone, a glucocorticoid believed to induce the CYP P450 enzyme, on the pharmacokinetics of odanacatib, a novel Cathepsin K…
Abstract Number: 799 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes Of Two Years Remission Steered Treatment In Early Arthritis Patients
L. Heimans¹, K.V.C. Wevers-de Boer¹, G. Akdemir¹, H.K Ronday², T.H.E. Molenaar³, J. H. L. M. Van Groenendael⁴, A.J. Peeters⁵, I. Speyer⁶, G. Collee⁷, P.B. de Sonnaville⁸, B.A. Grillet⁹, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Haga Hospital, The Hague, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Franciscus Hospital, Roosendaal, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Bronovo Hospital, Den Haag, Netherlands, ⁷MCH, The Hague, Netherlands, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To evaluate outcomes after 2 years of remission steered therapy in early arthritis patients. Methods: 610 patients with early rheumatoid or undifferentiated arthritis (UA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].